Events

Virtual AI Summit w/ Kevin Garwood and Peju Oshisanya

Panel Discussion: AI x Policy: Driving Responsible and Scalable Data Governance Best Practice – Looking Ahead at How External Stakeholders and Governmental Regulations Will Influence Data Strategy

  • Multinational companies – transferring and accessing data across borders, given different jurisdictions/laws/regulations
  • Brexit and the future of GDPR
  • European Union/US/China – what’s next in tech policy? How will it change tech investment and innovation? What does it mean for private companies?
  • Data Diversity
Speakers
  • Richard Self - Senior Lecturer in Governance of Advanced and Emerging Technologies, University of Derby
  • Eline Chivot - Senior Policy Analyst, Center for Data Innovation
  • Edwina Dunn - Co-Founder & Board Member, dunnhumby & Centre for Data Ethics & Innovation
  • Peju Oshisanya - Director – Clinical Programme Leader, Benevolent AI
  • Mike Wiley - Application CTO and VP Engineering, F5

Healthcare Track: Data Diversity Effort at BenevolentAI

→ Register here


Peju Oshisanya
AI Ethics, Data Diversity Advocate, Clinical Drug Development Leader at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Kevin Garwood
Patient Data Manager at BenevolentAI

Kevin is a patient data manager for precision medicine activities at BenevolentAI and is responsible for managing information governance concerns for patient-level data and in identifying and acquiring clinical and –omic data sources that would support our drug discovery programmes. Kevin’s interests include bioethics, intellectual property law and better understanding the value chain that shapes the worth and applicability of health data in the field of precision medicine. Most of his work involves coordinating with stakeholders from very different parts of the company.


More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022